DNDI-6174 / Eisai, DNDi - LARVOL DELTA

Quantitative analysis of DNDI-6174 using UPLC-MS/MS: A preclinical target site pharmacokinetic study. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "DNDI-6174 was stable under various conditions, including under tissue homogenization conditions, in all biomatrices investigated. This method was successfully applied in a translational study using a murine cutaneous leishmaniasis skin infection model to assess the target site pharmacokinetics of DNDI-6174, supporting its development as clinical candidate."

Journal • PK/PD data • Preclinical • Dermatology • Infectious Disease

DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc. (PubMed, Sci Transl Med) - "No major flags were identified in preliminary safety studies, including an exploratory 14-day toxicology study in the rat. DNDI-6174 is a cytochrome bc complex inhibitor with acceptable development properties to enter preclinical development for visceral leishmaniasis."

Journal • Preclinical • Infectious Disease